Welcome to our dedicated page for Marchex SEC filings (Ticker: MCHX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Marchex, Inc. filings document the regulatory record for a Delaware operating company that provides AI-based conversational intelligence and analytics solutions. Its disclosures cover operating and financial results, material agreements, capital-structure matters, governance actions, legal proceedings, and risk factors tied to its conversational analytics business.
Recent filings include Form 8-K material-event reports, proxy materials for annual meeting matters, and compensation disclosures involving cash awards, restricted stock units, stock options, and the 2021 Stock Incentive Plan. The filings also describe the company's Class A and Class B common stock voting structure, board and stockholder voting matters, lease-related agreements and impairments, and settlement documentation for civil litigation.
Marchex Inc. President & Chief Revenue Officer Troy Hartless exercised restricted stock units and received Class B common shares. On March 20, 2026, 87,500 restricted stock units converted into 87,500 shares of Class B Common Stock at a price of $0.00 per share. These units were granted effective March 20, 2025 and vested in full on the first anniversary of the grant date, making this a compensation-related equity delivery rather than an open-market purchase or sale. Following the conversion, this award’s derivative position is fully exercised and Hartless holds 87,500 Class B shares from this grant.
Marchex Inc Chief Financial Officer Brian Nagle exercised 7,500 restricted stock units into 7,500 shares of Class B Common Stock. The Form 4 shows a derivative exercise (code M) on March 20, 2026 at a stated price of $0.00 per unit.
According to the footnote, these restricted stock units were granted effective March 20, 2025 and vested in full on the first anniversary of the grant date. After the settlement, Nagle directly holds 7,500 shares of Class B Common Stock and no remaining units from this award. The filing reports no share sales or tax-withholding dispositions, indicating a routine compensation-related vesting and share issuance.
Marchex Inc. Chief Operating Officer & CLO Francis J. Feeney exercised 62,500 restricted stock units into the same number of Class B Common Stock shares. The units, granted effective March 20, 2025, vested in full on the first anniversary and converted at a zero exercise price as part of his equity compensation.
Marchex, Inc. approved new restricted stock unit grants for three senior executives as part of its annual compensation review. On February 17, 2026, Troy Hartless received 128,205 RSUs, Francis Feeney received 96,153 RSUs, and Brian Nagle received 56,089 RSUs.
Each RSU converts into one share of Class B Common Stock and vests in full on the first anniversary of the grant date, aligning these executives’ compensation with future company performance over the next year under the 2021 Stock Incentive Plan.
Nagle Brian reported acquisition or exercise transactions in this Form 4 filing.
Marchex Inc Chief Financial Officer receives new equity award. Brian Nagle was granted 56,089 restricted stock units effective February 17, 2026. The award was recorded at a price of $0.00 per unit, reflecting a non-cash grant.
Each restricted stock unit represents the right to receive one share of Marchex Class B common stock upon vesting. The units vest in full on the first anniversary of the grant date, meaning all 56,089 units are scheduled to vest one year after February 17, 2026, if conditions are met.
Marchex Inc reported an equity compensation grant to a senior executive. President & Chief Revenue Officer Troy Hartless acquired 128,205 restricted stock units effective February 17, 2026. Each unit represents one share of Class B common stock and will vest in full on the first anniversary of the grant date, increasing his direct equity-based stake if vesting conditions are satisfied.
Feeney Francis J reported acquisition or exercise transactions in this Form 4 filing.
Marchex Inc. reported that Chief Operating Officer & Chief Legal Officer Francis J. Feeney received a grant of 96,153 restricted stock units effective February 17, 2026. Each unit represents one share of Class B common stock and will vest in full on the first anniversary of the grant date, aligning his compensation with future company performance.
Marchex, Inc. approved annual cash bonuses for its senior executives for fiscal year 2025. The Compensation Committee granted a $200,000 bonus to President and Chief Revenue Officer Troy Hartless, $150,000 to Chief Operating Officer, Chief Legal Officer, and Corporate Secretary Francis Feeney, and $40,000 to Chief Financial Officer Brian Nagle.
Marchex, Inc. reported routine governance actions from its 2025 annual meeting and updated director compensation. On December 16, 2025, the Compensation Committee granted 50,000 stock options to each director under the 2021 Stock Incentive Plan, with an exercise price equal to the Class B common stock closing price that day. These options vest over two years, half on each of the first and second anniversaries of the grant date, and fully upon a Change in Control as defined in the plan. Independent directors will also receive $7,500 in cash per quarter for board service.
At the annual meeting, stockholders re-elected all director nominees. Marchex’s Class A shares carry 25 votes per share and Class B shares carry one vote per share, voting together as a single class on all matters unless law requires otherwise. Stockholders also approved the ratification of the company’s independent registered public accounting firm with 152,299,333 votes for, a small number of votes against or abstaining, and no broker non-votes.
Marchex Inc (MCHX) director receives new stock option grant. A company director was granted an employee stock option to buy 50,000 shares of Marchex Class B Common Stock at an exercise price of $1.64 per share, effective December 16, 2025. The option expires on December 16, 2035.
According to the vesting terms, 50% of the options vest on December 16, 2026 and the remaining 50% vest on December 16, 2027, assuming the director continues to serve on the Board through those dates. All of the options vest in full upon a Change of Control as defined in the director’s option agreement.